A Phase 1, Open-Label, 2-Part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [¹⁴C]-LY4515100 in Healthy Male Participants

Summary

The main purpose of this study is to evaluate how the body handles \[¹⁴C\]-LY4515100. The study will investigate how much \[¹⁴C\]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes \[¹⁴C\]-LY4515100 so that it can be used or removed, and how the body gets rid of \[¹⁴C\]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.

Eligibility

Age range

18–55 years

Sex

Male

Healthy volunteers

Yes

Interventions

• Drug
  [¹⁴C]-LY4515100 Oral Solution

  \[¹⁴C\]-LY4515100 administered orally

• Drug
  LY4515100 Tablet

  LY4515100 administered orally

• Drug
  [¹⁴C]-LY4515100 IV

  \[¹⁴C\]-LY4515100 administered IV

Location